Skin Microbiome & Barrier Patents: Leaders, Trends & Gaps 2026
- Filing peaked in 2019 at 52 records and has since fallen back toward the 2017 baseline, a pattern more consistent with a settled claim map than an emerging field.
- A61K carries 348 of 353 records while A61Q cosmetics-use claims sit under it at 265 — most filings are formulation and therapeutic-activity claims dressed as cosmetic products.
- Co-assignee filing is rare only 8 pairs across the whole dataset, and the strongest pair files together just 13 times — this is a field of solo filers, not joint ventures.
Filing growth compares 2021 (10 records) with 2024 (16) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 353 records in scope (CR5), not by the ranked leaders only.
A formulation-heavy field with a thinning filing curve
Patents tagged for skin microbiome and skin barrier function concentrate overwhelmingly in medicinal-preparation claims (A61K) rather than pure cosmetics-use claims (A61Q), which means most of what looks like a skincare patent is actually a formulation or therapeutic-activity claim wrapped in cosmetic language. The filing curve rose sharply to a 2019 peak of 52 records and has declined since, with the 2022 midpoint at just 11 — a shape that looks more like a technology that has already staked its claims than one still expanding.
Publication lags filing by roughly 18 months, so the last one or two years in any trend understate real filing activity — the 2026 figure of 1 record is a data artefact of the cut-off, not a collapse in interest. Reading the curve, the more useful signal is the 2019 peak and the subsequent decline through the 2022 midpoint, which together suggest the core claim space around barrier repair, transepidermal water loss (TEWL) mitigation and microbiome-friendly preservation was staked out early and has not been reopened by a second wave of filers.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
353 patent families published between 2015 and 2026, drawn from a search combining skin microbiome and barrier-function terminology with clinical-evaluation and preservation-compatibility qualifiers under A61K8, A61Q19 and A61K35.
A peak-and-decline curve, not a growth curve
Filings rose from 5 in 2017 to a peak of 52 in 2019, then fell back toward single digits by the 2022 midpoint of 11 records — the opposite of the steady climb seen in genuinely emerging technology areas.
Medicinal preparations dominate over pure cosmetics claims
A61K appears in 348 of 353 records against 265 for A61Q, with A61P therapeutic-activity classification present in 146 — a strong indication that barrier-function claims are being drafted with pharmaceutical breadth rather than narrow cosmetic-use language.
Shares are the percentage of the 353 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Skin Microbiome and Barrier Science with Eureka
This page is one run against one query. Ask Eureka your own question about skin microbiome and barrier science and every answer comes back with the patent numbers behind it.
Try EurekaThe records other filings build on
Composition for preventing or reducing transepidermal water loss and improving skin barrier function
The patent covers use of a milk whey protein hydrolysate for preventing or treating transepidermal water loss and TEWL-associated disorders — including atopic dermatitis, dry or reactive skin and skin dehydration — and for enhancing skin barrier function, with claimed use extending across both young and adult mammals and into general cosmetic skin-appearance improvement.Filed by Societe des Produits Nestle S.A., published 2024-08-20 as US12064506B2.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6503526B1 | Absorbent articles enhancing skin barrier function | 110 |
| 2 | US6028118A | Methods of using extracts of shark cartilage | 55 |
| 3 | WO1997016197A1 | Extracts of shark cartilage | 45 |
| 4 | WO2017083398A1 | Compositions and methods for application over skin | 36 |
| 5 | US20160317432A1 | Compositions And Methods For Improving Skin Health | 33 |
| 6 | US20200179460A1 | Reducing the Likelihood of Skin Cancer in an Individual Human Being | 31 |
| 7 | US20220118031A1 | Method and System to Improve the Health of a Person's Skin Microbiome | 29 |
| 8 | US10111913B2 | Method of reducing the likelihood of skin cancer in an individual human being | 29 |
| 9 | US10314866B2 | Method of reducing the likelihood of skin cancer in an individual human being | 28 |
| 10 | JP2005189011A | Method of differentiating skin barrier function | 28 |
Citation counts favour older records that have had more time to accumulate citations within this searched corpus; treat them as a signal of influence, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern says about the field
Three signals stand out once the raw counts are set against each other: a peaked-and-declining trend, a jurisdiction mix tilted toward the US and Europe, and a citation table still dominated by decade-old absorbent-article and shark-cartilage extract art.
The field peaked and has been declining since
From 5 records in 2017, filings climbed to 52 in 2019 before falling back to 11 by the 2022 midpoint. That shape is consistent with a claim space that was staked out quickly rather than one still being built.
Filing effort concentrates in the US and Europe
The United States and the European Patent Office together account for the largest share of receiving-office filings, with WIPO PCT filings a distant third at 41 and Japan, Australia and China each in the teens.
The most-cited prior art predates the microbiome framing
The single most-cited record in the corpus, US6503526B1 on absorbent articles enhancing skin barrier function, carries 110 citations — older general barrier-function and shark-cartilage extract art still anchors the citation graph more than recent microbiome-specific filings.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to skin microbiome and barrier science, with the prior art for and against each one.
A field of solo filers, not alliances
Only 8 co-assignee pairs appear across 353 families, and the strongest of them files together just 13 times — most organisations in this space file independently rather than through joint development structures.
Joint filing is the exception
Across the whole dataset only 8 co-assignee pairs exist, the strongest linking two entities on 13 shared families. Most assignees, including the largest cosmetics and consumer-goods groups in the corpus, file under a single corporate name.
Recent-year activity has gone flat across former leaders
Several of the assignees with the deepest filing history in this corpus show zero filings in the latest recorded year, with year-over-year declines of -100% where a prior-year baseline exists — consistent with the field-wide peak-and-decline trend rather than any single company retreating.
Where co-filing exists, it runs through corporate affiliates
The strongest co-assignee relationships in the dataset link a parent and its regional or research affiliate rather than two unrelated competitors, a pattern typical of internal IP-holding structures rather than external collaboration.
| Assignee | Recent year | YoY |
|---|---|---|
| Shiseido Company, Limited | 0 | -100% |
| POLA Chemical Industries, Inc. | 0 | — |
| Amazentis SA | 0 | -100% |
| Shiseido Americas Corporation | 0 | — |
| Symrise AG | 0 | — |
| Bioibérica S.A.U. | 0 | — |
| Probi AB | 0 | — |
| DSM IP Assets B.V. | 0 | — |
Where to take this next
The filing curve and citation base point to a field with an established core and a thin recent layer — the open questions are about where that core can still be extended.
Map the white space chips against your own pipeline
The under-claimed branches listed above sit next to dense prior art rather than in empty territory — checking a candidate formulation against both is more useful than checking against the dense core alone.
Explore in Eureka →Track whether momentum resumes past the 2026 cut-off
Because publication lags filing by around 18 months, the true trajectory of 2024-2025 filings will not be visible in public data until later; revisit the trend once that lag clears.
Set up monitoring in Eureka →Common questions on this landscape
Not on the evidence in this corpus. Filings rose from 5 in 2017 to a peak of 52 in 2019, then declined to 11 by the 2022 midpoint, which is a peak-and-decline shape rather than a growth curve. The very low count in 2025-2026 partly reflects publication lag of roughly 18 months rather than a sudden stop, but the decline visible well before that lag window is real. A practitioner should read this as a field where the core claim space was staked out quickly rather than one still opening up.
By citation count within this corpus, the most-cited record is US6503526B1 on absorbent articles enhancing skin barrier function, followed by older shark-cartilage extract patents and more recent compositions for skin health improvement. These citation counts favour older filings that have simply had more time to accumulate citations, so treat the table as a map of historical influence rather than a ranking of current commercial importance.
US12064506B2, assigned to Societe des Produits Nestle S.A. and published August 2024, covers use of a milk whey protein hydrolysate for preventing or treating transepidermal water loss and related disorders including atopic dermatitis, dry skin and skin dehydration, plus general cosmetic skin-appearance improvement. Its scope spans both young and adult mammals, which is broader than a typical adult-only cosmetic claim. Anyone formulating a whey-protein-hydrolysate-based barrier or TEWL product should review this filing's specific claim language before proceeding.
348 of 353 records in this corpus carry an A61K medicinal-preparation classification against 265 for A61Q cosmetics-use, meaning most filings are drafted with pharmaceutical-style breadth even when the product is sold as a cosmetic. This matters practically: a barrier-repair or TEWL claim filed under A61K can carry broader therapeutic scope than a narrowly drafted cosmetic-use claim, which is one reason the citation graph and claim language in this field skews toward treatment of disorders like atopic dermatitis rather than pure appearance improvement.
Overwhelmingly alone. Only 8 co-assignee pairs exist across all 353 families in this dataset, and the strongest pairing files together just 13 times. Where co-filing does appear, it tends to link a parent company with its own regional or research affiliate rather than two independent competitors, so this is not a field characterised by cross-company joint ventures or shared IP pools.
Research Skin Microbiome and Barrier Science in depth with Eureka
Go past this page: query the whole skin microbiome and barrier science corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.